IMUNON to Host Virtual R&D Day on September 14th Beginning at 4

00 p.m. ET

Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development

LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that it will hold a virtual R&D Day event on September 14^th beginning at 4:00 p.m. Eastern time. Details about speakers and instructions on how to participate are below.

The Event’s Speakers

IMUNON presenters include:

• Dr. Corinne Le Goff, President and Chief Executive Officer
• Khursheed Anwer, Ph.D., Executive Vice President and Chief Science Officer

Guest key opinion leader presenters include:

• Sallie Permar, M.D., Ph.D., Chair of the Department of Pediatrics at Weill Cornell Medicine and Pediatrician-in-Chief at New York-Presbyterian/Weill Cornell Medical Center and New York-Presbyterian Komansky Children’s Hospital. She is also Nancy C. Paduano Professor and Chair, Weill Cornell Medicine.
• Patrick Ott, M.D., Ph.D., Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute. He is also an attending physician in the Department of Medicine at Brigham and Women's Hospital and is an Associate Professor at Harvard Medical School.

Dr. Permar will focus her presentation on the “Vaccines of the Future” while Dr. Ott will discuss “Immuno-Oncology: The remaining unmet need.”

Dr. Permar is a physician-scientist focusing on the prevention and treatment of neonatal viral infections and leads a research laboratory investigating immune protection against vertical transmission of neonatal viral pathogens, namely HIV and cytomegalovirus. Dr. Ott is a clinical investigator and a member of the clinical trials program at Dana Farber/Harvard Cancer Center, where he designs and conducts Phase 1 immunotherapy trials for patients with melanoma and other tumors.

How to Participate

The virtual program will be held online beginning at 4:00 p.m. Eastern Time and is expected to last approximately 90 minutes. There is no need to pre-register for the event. A live and archived webcast will be available in the Scientific Presentations section of IMUNON’s website. Following management’s presentations, a Q&A session will be available via the chat function of the webcast.